Jump Financial LLC Grows Position in Evolus, Inc. $EOLS

Key Points

• Jump Financial LLC increased its stake in Evolus, Inc. by 171.4% during the first quarter, owning about 116,982 shares valued at approximately $1.41 million.
• Institutional investors collectively hold about 90.69% of Evolus's shares, indicating significant institutional interest in the company.
• Recent analyst ratings show mixed sentiments, with targets reducing from as high as $27 to a current average of $21.25, while rating updates fluctuate between "buy," "hold," and "sell."

Jump Financial LLC raised its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 171.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,982 shares of the company's stock after purchasing an additional 73,882 shares during the period. Jump Financial LLC owned about 0.18% of Evolus worth $1,407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Tang Capital Management LLC raised its position in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after purchasing an additional 150,000 shares in the last quarter. Vanguard Group Inc. raised its position in Evolus by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after purchasing an additional 62,664 shares in the last quarter. Caligan Partners LP raised its position in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after purchasing an additional 498,900 shares in the last quarter. Millennium Management LLC lifted its holdings in Evolus by 29.1% during the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock worth $15,107,000 after buying an additional 308,753 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Evolus during the 1st quarter worth about $12,330,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Wall Street Analysts Forecast Growth

EOLS has been the topic of several research analyst reports. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. HC Wainwright reduced their target price on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. BTIG Research decreased their target price on Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Finally, Needham & Company LLC restated a "hold" rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.25.

Evolus Stock Performance

EOLS traded down $0.14 on Wednesday, hitting $7.36. 64,248 shares of the company traded hands, compared to its average volume of 1,091,282. The company has a 50 day moving average of $8.36 and a 200-day moving average of $10.31. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. The stock has a market capitalization of $476.04 million, a PE ratio of -7.51 and a beta of 1.07. Evolus, Inc. has a 12-month low of $5.71 and a 12-month high of $17.82.

Insiders Place Their Bets

In other news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total transaction of $42,972.22. Following the completion of the transaction, the chief marketing officer directly owned 89,949 shares of the company's stock, valued at approximately $675,516.99. This represents a 5.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Albert G. White III acquired 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were acquired at an average cost of $9.45 per share, for a total transaction of $189,000.00. Following the acquisition, the director directly owned 50,378 shares of the company's stock, valued at $476,072.10. This trade represents a 65.84% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders sold 133,627 shares of company stock valued at $1,325,764. Corporate insiders own 6.10% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.